Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 12/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24579905 | 0.89 | FABP7 (0.37) | FABP7FABP5FKBP1A | |
| SCHEMBL25657678 | 0.88 | FABP7 (0.36) | FABP7FABP5TSHR | |
| SCHEMBL25657679 | 0.85 | FABP7 (0.36) | FABP7FABP5GFERMEN1KMT2A | |
| SCHEMBL28773187 | 0.83 | FABP7 (0.39) | FABP7FABP5 | |
| SCHEMBL29696667 | 0.83 | ALDH1A1 (0.41) | FABP7FABP5FKBP1A | |
| SCHEMBL26448326 | 0.80 | PRCP (0.40) | — | |
| SCHEMBL25657668 | 0.80 | FABP5 (0.38) | FABP7FABP5KMT2ACTSBCTSS | |
| SCHEMBL28773174 | 0.79 | FABP5 (0.38) | FABP7FABP5 | |
| SCHEMBL25658698 | 0.79 | FFAR2 (0.36) | FABP7FABP5 | |
| SCHEMBL25658700 | 0.79 | FFAR2 (0.36) | FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | EEF1A1, EEF1B2, EEF1G | FABP7 3324/4885FABP5 3327/4885TSHR 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.